Fran Balkwill

Q: What Schools Are Affiliated With Fran Balkwill

Fran Balkwill is affiliated with the following schools: Institute of Cancer Research, University of Oxford, Queen Mary University of London

Fran Balkwill's AcademicInfluence.com Rankings

Fran Balkwill

Philosophy

#2890

World Rank

#4794

Historical Rank

Logic

#830

World Rank

#1379

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Fran Balkwill Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Frances Rosemary Balkwill is an English scientist, Professor of Cancer Biology at Queen Mary University of London, and author of children's books about scientific topics. Early life and education Balkwill was born in south-west London in 1952, and was educated at Surbiton High School. She obtained a BSc in Cellular Pathology at the University of Bristol and a PhD on leukaemia cell biology in the Medical Oncology Department at St Bartholomew's Hospital supervised by Gordon Hamilton Fairley.

(See a Problem?)

Fran Balkwill's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Cancer-related inflammation (2008) (9454)
Inflammation and cancer: back to Virchow? (2001) (7014)
Cancer and the chemokine network (2004) (2299)
Smoldering and polarized inflammation in the initiation and promotion of malignant disease. (2005) (1758)
Tumour necrosis factor and cancer (2009) (1648)
The tumor microenvironment at a glance (2012) (1314)
Guidelines for the welfare and use of animals in cancer research (2010) (1225)
Rethinking ovarian cancer: recommendations for improving outcomes (2011) (1148)
The cytokine network. (1989) (842)
Inflammation and cancer: advances and new agents (2015) (803)
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer (2015) (778)
“Re-educating” tumor-associated macrophages by targeting NF-κB (2008) (767)
The significance of cancer cell expression of the chemokine receptor CXCR4. (2004) (761)
Cancer: An inflammatory link (2004) (677)
TNF-α in promotion and progression of cancer (2006) (663)
Paraneoplastic thrombocytosis in ovarian cancer. (2012) (636)
Cancer-related inflammation: common themes and therapeutic opportunities. (2012) (597)
CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma (2016) (555)
Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis (1999) (550)
Tumor necrosis factor or tumor promoting factor? (2002) (533)
Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. (2002) (497)
Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. (1993) (458)
EVIDENCE FOR TUMOUR NECROSIS FACTOR/CACHECTIN PRODUCTION IN CANCER (1987) (429)
Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. (1999) (417)
Ovarian Cancer Cells Polarize Macrophages Toward A Tumor-Associated Phenotype1 (2006) (409)
A guiding map for inflammation (2017) (402)
A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. (1993) (398)
Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. (2004) (393)
Macrophages Induce Invasiveness of Epithelial Cancer Cells Via NF-κB and JNK1 (2005) (389)
The chemokine system and cancer (2012) (389)
TNF-alpha in promotion and progression of cancer. (2006) (371)
Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. (1997) (371)
The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. (2007) (366)
Activity of type IV collagenases in benign and malignant breast disease. (1993) (360)
Epithelial cancer cell migration: a role for chemokine receptors? (2001) (357)
Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer (2011) (353)
Tumour necrosis factor-α as a tumour promoter (2006) (343)
Tumour necrosis factor α: a potential target for the therapy of solid tumours (2003) (328)
Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. (1996) (328)
The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. (1995) (317)
Zymography: a single-step staining method for quantitation of proteolytic activity on substrate gels. (1997) (300)
The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. (2009) (292)
B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis (2011) (290)
A chemokine receptor antagonist inhibits experimental breast tumor growth. (2003) (275)
Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. (1993) (264)
Chemokine biology in cancer. (2003) (257)
Cancer and Inflammation: Implications for Pharmacology and Therapeutics (2010) (251)
Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. (2007) (250)
Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. (2005) (239)
Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions. (1992) (238)
IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer (2011) (225)
Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. (1986) (223)
Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice. (2011) (216)
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. (2001) (213)
The chemokine network in cancer--much more than directing cell movement. (2004) (210)
Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. (2018) (206)
Chemokine stimulation of monocyte matrix metalloproteinase‐9 requires endogenous TNF‐α (2002) (205)
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors (2013) (205)
Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. (2003) (196)
A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. (2012) (189)
The role of cytokines in the epithelial cancer microenvironment. (2002) (182)
Expression and activity of MMPS and their regulators in ovarian cancer (1994) (178)
Tumour necrosis factor-alpha as a tumour promoter. (2006) (176)
A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. (2008) (175)
Central nervous system toxicity of interferon. (1983) (174)
Expression of both TNF-α receptor subtypes is essential for optimal skin tumour development (2004) (174)
Interferon affects both G1 and S+G2 in cells stimulated from quiescence to growth (1978) (174)
Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. (2006) (170)
Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. (2005) (161)
In vivo Loss of Expression of Argininosuccinate Synthetase in Malignant Pleural Mesothelioma Is a Biomarker for Susceptibility to Arginine Depletion (2006) (159)
Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers (2010) (159)
Tumour necrosis factor (1989) (158)
Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. (1990) (158)
Interleukin-6 Stimulates Defective Angiogenesis. (2015) (157)
Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation – a potential mechanism (2001) (156)
Murine CD27(−) Vγ6(+) γδ T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages (2014) (155)
Phase I Study of Bryostatin 1: Assessment of Interleukin 6 and Tumor Necrosis Factor α Induction In Vivo (1993) (153)
The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. (2005) (153)
Characterization of the Extracellular Matrix of Normal and Diseased Tissues Using Proteomics. (2017) (151)
A cytokine profile of normal and malignant ovary. (1996) (151)
An Anti-Tumor Necrosis Factor-α Antibody Inhibits the Development of Experimental Skin Tumors (2003) (146)
Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. (2002) (145)
Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system. (1984) (144)
CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype (2018) (144)
IL‐12 regulates VEGF and MMPs in a murine breast cancer model (1998) (143)
Defective Expression of the Monocyte Chemotactic Protein-1 Receptor CCR2 in Macrophages Associated with Human Ovarian Carcinoma1 (2000) (142)
Inflammation and cancer: a double-edged sword. (2007) (142)
INTERFERONS (1989) (138)
Endothelin‐2 is a macrophage chemoattractant: implications for macrophage distribution in tumors (2002) (135)
Ovarian cancer cell–derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis (2007) (135)
DNA fragmentation and cytotoxicity caused by tumor necrosis factor is enhanced by interferon‐γ (1987) (134)
Expression and regulation of tumor necrosis factor α in normal and malignant ovarian epithelium (2006) (129)
Hypoxia inhibits macrophage migration (1999) (122)
Tumour necrosis factor-α mediates tumour promotion via a PKCα- and AP-1-dependent pathway (2002) (120)
Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. (2004) (120)
A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases (2016) (117)
A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor α Inhibitor in Patients with Metastatic Breast Cancer (2004) (110)
Activity of human monocytes in IgE antibody‐dependent surveillance and killing of ovarian tumor cells (2003) (110)
B regulatory cells in cancer. (2013) (109)
Harnessing cytokines and chemokines for cancer therapy (2022) (108)
A Role for Endothelin-2 and Its Receptors in Breast Tumor Cell Invasion (2004) (106)
Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma (2016) (105)
Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours (2001) (103)
Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF). (1998) (102)
Paradoxical effects of tumour necrosis factor in experimental ovarian cancer (1989) (102)
Hypoxia down‐regulates MCP‐1 expression: implications for macrophage distribution in tumors (1998) (102)
CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma. (2016) (102)
Cytokines : a practical approach (1991) (101)
IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. (2007) (101)
Inhibition by lymphoblastoid interferon of growth of cells derived from the human breast (1978) (99)
THE role of indoleamine 2,3‐dioxygenase in the anti‐tumour activity of human interferon‐γ in vivo (1995) (97)
TNF-α regulates epithelial expression of MMP-9 and integrin αvβ6 during tumour promotion. A role for TNF-α in keratinocyte migration? (2004) (92)
An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors. (2003) (89)
Intraperitoneal xenografts of human epithelial ovarian cancer in nude mice. (1987) (89)
Augmentation of cytotoxicity of chemotherapy by human alpha-interferons in human non-small cell lung cancer xenografts. (1986) (87)
Low-Dose IFN-γ Induces Tumor MHC Expression in Metastatic Malignant Melanoma (2003) (85)
Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells. (2002) (83)
Cytokines in health and disease. (1993) (82)
Investigation of cytokine gene expression in human colorectal cancer. (1990) (75)
Cancer associated fibroblast FAK regulates malignant cell metabolism (2020) (72)
In situ detection of tumour necrosis factor in human ovarian cancer specimens. (1990) (70)
IFN-γ Induces Apoptosis in Ovarian Cancer Cells in Vivo and in Vitro (2003) (69)
Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway. (2002) (68)
An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells (2009) (67)
Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells (2007) (67)
Therapeutic Potential of Tumor Necrosis Factor-α and γ-Interferon in Experimental Human Ovarian Cancer (1987) (66)
Growth inhibitory effects of interferon on normal and malignant human haemopoietic cells (1977) (66)
The ppp(A2'p)nA and protein kinase systems in wild-type and interferon-resistant Daudi cells. (2005) (65)
MMP-2 release and activation in ovarian carcinoma: the role of fibroblasts (1999) (65)
Reduced Expression of Histone Methyltransferases KMT2C and KMT2D Correlates with Improved Outcome in Pancreatic Ductal Adenocarcinoma. (2016) (64)
Vaccinia Virus Induces Programmed Necrosis in Ovarian Cancer Cells (2013) (64)
Human T-Lymphotropic Virus Type 1-Induced CC Chemokine Ligand 22 Maintains a High Frequency of Functional FoxP3+ Regulatory T Cells (2010) (63)
A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer (2017) (61)
Cytotoxic response of ovarian cancer cell lines to IFN-γ is associated with sustained induction of IRF-1 and p21 mRNA (1999) (61)
IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro. (2003) (60)
Positive interactions between interferon and chemotherapy due to direct tumor action rather than effects on host drug-metabolizing enzymes. (1984) (58)
Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. (1993) (58)
The molecular and cellular biology of the chemokines (1998) (57)
Experimental validation of a flat punch indentation methodology calibrated against unconfined compression tests for determination of soft tissue biomechanics. (2016) (57)
Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma. (2003) (57)
Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer (2019) (57)
Epithelial ovarian cancer: a cytokine propelled disease? (1991) (56)
Discrepancies in the Tumor Microenvironment of Spontaneous and Orthotopic Murine Models of Pancreatic Cancer Uncover a New Immunostimulatory Phenotype for B Cells (2019) (55)
Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours (2019) (54)
Cancer cell‐derived lymphotoxin mediates reciprocal tumour–stromal interactions in human ovarian cancer by inducing CXCL11 in fibroblasts (2014) (54)
The peritoneal tumour microenvironment of high-grade serous ovarian cancer (2012) (52)
The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients. (1999) (52)
Tumour necrosis factor as an anticancer agent. (1990) (52)
The cytokine wall chart. (1993) (51)
TNF-alpha regulates epithelial expression of MMP-9 and integrin alphavbeta6 during tumour promotion. A role for TNF-alpha in keratinocyte migration? (2004) (49)
Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment (2020) (48)
Chemotherapy, immunity and microbiota—a new triumvirate? (2014) (48)
Cytokines in Cancer Therapy (1989) (48)
Differential effects of recombinant interferon alpha on constitutive and inducible cytochrome P450 isozymes in mouse liver. (1991) (47)
Multiple molecular and cellular changes associated with tumour stasis and regression during IL‐12 therapy of a murine breast cancer model (1998) (46)
Sex, Cytokines, and Cancer (2007) (45)
Enhanced metastases of a mouse carcinoma after in vitro treatment with murine interferon gamma (1987) (45)
Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: enhancement of effect by batimastat. (1997) (44)
TNF: a tumor-suppressing factor or a tumor-promoting factor? (2010) (44)
Effects of interferons and other cytokines on tumors in animals: a review. (1991) (44)
Human ovarian surface epithelial cells immortalized with hTERT maintain functional pRb and p53 expression (2007) (42)
Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells. (2009) (42)
Human lymphoblastoid interferon can inhibit the growth of human breast cancer xenografts in athymic (nude) mice. (1980) (41)
Enhancement by gamma-interferon of in vivo tumor radiolocalization by a monoclonal antibody against HLA-DR antigen. (1986) (41)
Aberrant regulation of argininosuccinate synthetase by TNF‐α in human epithelial ovarian cancer (2007) (41)
Cytokines in tumour growth, migration and metastasis (2004) (40)
Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer. (2015) (40)
INTERFERONS IN CANCER THERAPY: A REAPPRAISAL (1987) (40)
Enhancement of metastatic potential by γ-interferon (1991) (39)
Involvement of both intrinsic and extrinsic pathways in IFN-gamma-induced apoptosis that are enhanced with cisplatin. (2005) (38)
A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro (2004) (37)
Antitumor Activity of γ-Interferon in Ascitic and Solid Tumor Models of Human Ovarian Cancer (1991) (36)
A novel function of colony-stimulating factor 1 receptor in hTERT immortalization of human epithelial cells (2009) (35)
A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer (2003) (35)
Aberrant regulation of argininosuccinate synthetase by TNF-alpha in human epithelial ovarian cancer. (2007) (35)
Association between biosynthesis of nitric oxide and changes in immunological and vascular parameters in patients treated with interleukin‐2 (1994) (34)
Cytokines--soluble factors in immune responses. (1988) (33)
The Anti-proliferative Activity of Interferon-γ on Ovarian Cancer: In Vitro and in Vivo (2003) (32)
Changes in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumour necrosis. (1995) (32)
The effect of recombinant human tumour necrosis factor on growth and macromolecular synthesis of human epithelial cells. (1987) (31)
Implications for clinical application of new developments in interferon research. (1982) (31)
Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer (2004) (30)
Interferon gamma regulates HLA-D expression on solid tumors in vivo. (1987) (29)
Differential effects of pure human alpha and gamma interferons on fibroblast cell growth and the cell cycle. (1984) (29)
TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer (2021) (29)
Immune human lymphocytes produce an acid-labile α-interferon (1983) (29)
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference (2019) (29)
Tumour necrosis factor and cancer. (1992) (28)
A paralytic disease in nude mice associated with polyoma virus infection. (1983) (28)
Characterization of human breast milk macrophages cytostatic for human cell lines. (1979) (26)
Human small‐cell lung‐cancer cells are cytokine‐resistant but NK/LAK‐sensitive (1991) (25)
Specific Mechanisms of Chromosomal Instability Indicate Therapeutic Sensitivities in High-Grade Serous Ovarian Carcinoma (2020) (24)
Effects of HuIFN-α2 and HuIFN-α (Namalwa) on breast cancer cells grown in culture and as xenografts in the nude mouse (1982) (24)
Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSF. (1991) (24)
Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness. (2019) (23)
Growth of acute myeloid leukaemia as discrete subcutaneous tumours in immune-deprived mice. (1977) (23)
Demyelination and wasting associated with polyomavirus infection in nude (nu/nu) mice (1980) (22)
Human interferons inhibit experimental metastases of a human melanoma cell line in nude mice. (1988) (21)
RalB Signaling: A Bridge between Inflammation and Cancer (2006) (21)
Cancer. Sex, cytokines, and cancer. (2007) (21)
Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer (2013) (21)
Exploiting changes in the tumour microenvironment with sequential cytokine and matrix metalloprotease inhibitor treatment in a murine breast cancer model (2000) (21)
TNF is here to stay! (2000) (20)
Induction and suppression of glutathione transferases by interferon in the mouse. (1987) (20)
Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. (2008) (20)
Preclinical and clinical studies of interferons and interferon inducers in breast cancer (1984) (20)
An introduction to cytokines (1993) (19)
p21 promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker (2010) (19)
Enhancement of metastatic potential by gamma-interferon. (1991) (19)
Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2. (1992) (19)
A human multi-cellular model shows how platelets drive production of diseased extracellular matrix and tissue invasion (2021) (19)
A phase I study of human lymphoblastoid interferon administered by continuous intravenous infusion (2004) (18)
Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression. (2011) (18)
Diagnostic and prognostic significance of peripheral blood cultural characteristics in adult acute leukaemia. (1976) (17)
Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium (2011) (17)
Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma (2020) (16)
2′,5′-Oligoadenylate Synthetase and Interferon in Peripheral Blood after Rubella, Measles, or Mumps Live Virus Vaccine (1987) (15)
Cytokines in animal models of cancer (1996) (15)
Antiviral and antiproliferative effects of interferons in quiescent fibroblasts are dissociable. (1985) (15)
Cytokine therapy of cancer. The importance of knowing the context. (1994) (15)
Monoclonal antibodies that distinguish between subspecies of human interferon-alpha and that detect interferon oligomers. (1984) (15)
Cytokine molecular biology : a practical approach (2000) (15)
Interferons as cell-regulatory molecules (1979) (15)
Pancreatic Cancer Chemotherapy Is Potentiated by Induction of Tertiary Lymphoid Structures in Mice (2021) (14)
Temporal sequence and cellular origin of interleukin-2 stimulated cytokine gene expression. (1993) (14)
An inbred colony of oncogene transgenic mice: diversity of tumours and potential as a therapeutic model. (1996) (14)
Factors influencing microculture of leukaemia cells (1974) (14)
Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust. (2003) (14)
An Animal Model System for Investigating the AntiTumor Effects of Human Interferon (1983) (14)
USE OF INTERFERON IN THE MANAGEMENT OF PATIENTS WITH SUBACUTE SCLEROSING PANENCEPHALITIS (1985) (14)
Antiproliferative and antitumor activity of TNF in vitro and in vivo. (1992) (13)
Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cells (2016) (13)
The anti-proliferative activity of interferon-gamma on ovarian cancer: in vitro and in vivo. (2003) (12)
Cytokine cell biology : a practical approach (2000) (12)
Improving on the formula (1993) (12)
Assessing new anti-tumour agents and strategies in oncogene transgenic mice (1995) (11)
Modelling TGFβR and Hh pathway regulation of prognostic matrisome molecules in ovarian cancer (2021) (11)
Cytokine amplification and inhibition of immune and inflammatory responses (1997) (10)
Immunology for the next generation (2005) (10)
The inflammatory cytokine network of epithelial cancer: therapeutic implications. (2004) (10)
Central nervous system toxicity of interferon. (1985) (9)
Reconstitution of interleukin 2 with albumin for infusion (1990) (9)
Interferons in oncology: current status and future directions. (1987) (9)
Multiple myeloma: An immunoclinical study of disease and response to treatment (1995) (8)
Chemotherapy Induces Tumor-Associated Macrophages that Aid Adaptive Immune Responses in Ovarian Cancer (2021) (8)
Interest and learning in informal science learning sites: Differences in experiences with different types of educators (2020) (8)
Oncogene transgenic mice as therapeutic models in cancer research. (1994) (8)
Effects of intraperitoneal recombinant interleukin-1 beta in intraperitoneal human ovarian cancer xenograft models: comparison with the effects of tumour necrosis factor. (1992) (8)
Learning hand in hand: Engaging in research–practice partnerships to advance developmental science (2020) (8)
The Relations and Role of Social Competencies and Belonging with Math and Science Interest and Efficacy for Adolescents in Informal STEM Programs (2020) (8)
Interferons alpha and gamma differ in their ability to cause tumour stasis and regression in vivo. (1989) (7)
Interferons: from molecular biology to man. Part 1. Genetics and molecular biology of the interferon system. (1986) (7)
Experience with human lymphoblastoid interferon in acute myelogenous leukaemia (AML) (2004) (7)
The effect of cytokines on cultured mononuclear cells from patients with B cell chronic lymphocytic leukemia (1993) (7)
Effects of tumour necrosis factor on human tumour xenografts in nude mice. (2007) (7)
HUMAN LYMPHOBLASTOID INTERFERON CAN INHIBIT THE GROWTH OF HUMAN BREAST CANCER XENOGRAFTS IN ATHYMIC [NUDE] MICE (1980) (7)
Species restriction in cytostatic activity of human and murine monocytes and macrophages. (1981) (6)
Tumour necrosis factor (1988) (6)
Cytokines and ovarian cancer (1995) (6)
Discussion: Immunological Therapeutics in Ovarian Cancer (2003) (5)
Antitumor activity of gamma-interferon in ascitic and solid tumor models of human ovarian cancer. (1991) (5)
Fusion potential for vaccines (1993) (5)
Animal models for investigating antitumor effects of interferon. (1986) (5)
Safety of medicines and the use of animals in research (2011) (5)
The complex effects of recombinant tumour necrosis factor-alpha (rhTNF-alpha) in human ovarian cancer xenograft models. (1990) (5)
Interferons and cytokines on a grand scale. (1997) (5)
Re: Possible Role of Ovarian Epithelial Inflammation in Ovarian Cancer. (2000) (5)
“ Re-educating ” tumor-associated macrophages by targeting NF- (cid:3) B (2008) (4)
Cancer Therapy : Clinical IL 6-STAT 3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer (2011) (4)
Centre of the Cell: Science Comes to Life (2015) (4)
Beta actin expression and organization of actin filaments in colorectal neoplasia. (1992) (4)
Loss of mTORC2‐induced metabolic reprogramming in monocytes uncouples migration and maturation from production of proinflammatory mediators (2021) (4)
A phase I study of human lymphoblastoid interferon in patients with hematological malignancies. (1981) (4)
Tumor Cells in Human Ovarian Cancer Multiple Actions of the Chemokine CXCL 12 on Epithelial Updated (2002) (3)
Airway dendritic cell maturation in children exposed to air pollution (2020) (3)
A Darker Side to Retinoic Acid Revealed by Sarcomas. (2020) (3)
Building invitro 3D human multicellular models of high-grade serous ovarian cancer (2022) (3)
Summary: Current Status and Future Directions (1987) (3)
The anti-cancer activity of tumour necrosis factor. (1988) (3)
Therapeutic potential of tumor necrosis factor-alpha and gamma-interferon in experimental human ovarian cancer. (1987) (3)
A therapeutically actionable pro-tumoral axis of cytokines involving interleukin-8, TNFa and IL-1B. (2022) (3)
Organ-on-a-chip: current gaps and future directions (2022) (3)
Translation manual (1996) (3)
Mechanisms of Chromosomal Instability in High-grade Serous Ovarian Carcinoma (2019) (3)
The Tumor Microenvironment of Clear-Cell Ovarian Cancer (2022) (3)
Interferon in acute myelogenous leukaemia: a preliminary report. (1983) (3)
Impact of Pericytes on the Stabilisation of Microvascular Networks in Microfluidic Systems in Response to Nanotoxicity (2022) (3)
hTERT Immortalised Human Ovarian Surface Epithelial Cells Maintain Functional pRb and p53 Expression (2007) (2)
IL-6 and Ovarian Cancer—Response (2011) (2)
Author Correction: A guiding map for inflammation (2020) (2)
Membrane Activation in Immunologically Relevant Cells (1989) (2)
Cells Are Us (1990) (2)
Abstract 1076: Antagonists of the chemokine receptor CCR4 reverse the tumor-promoting microenvironment of renal cancer (2014) (2)
The Inflammatory Tissue Microenvironment and the Early Stages of Malignancy (2011) (2)
DNA Is Here to Stay (1992) (2)
Erratum to “Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis” (1999) (2)
Amazing Schemes Within Your Genes (1993) (2)
Cells are Us – combining research and public engagement (2021) (2)
Tumour necrosis factor. Improving on the formula. (1993) (2)
Abstract 2217: Pegylated arginine deiminase sensitizes ASS1-negative and KRAS mutant non-small cell lung cancer to PD-1 blockade immunotherapy (2020) (2)
The Links between Inflammation and Cancer (2007) (2)
Stromal Cells Promote Matrix Deposition, Remodelling and an Immunosuppressive Tumour Microenvironment in a 3D Model of Colon Cancer (2021) (2)
TNF biosynthesis in gut associated immunopathologies (1999) (2)
A PHASE II STUDY OF ETANERCEPT (ENBREL), A TUMOUR NECROSIS FACTOR-ALPHA INHIBITOR IN RECURRENT OVARIAN CANCER (2004) (2)
Interleukin-6 as a therapeutic target in advanced ovarian cancer. (2010) (2)
Abstract 693: TGFβ-mediated targeting of the extracellular matrix enhances the migration and cytotoxicity of CAR-T cells in 3D models of ovarian cancer (2022) (2)
Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer (2022) (1)
Chemokines and Gynecologic Malignancies (1999) (1)
Interferons: from molecular biology to man. Part 3. Interferons and disease. (1986) (1)
Abstract 1103: The effects of neo-adjuvant chemotherapy on myeloid cells in high-grade serous ovarian cancer metastases (2019) (1)
Molecular networks. Cytokines (1990). By Anthony Meager. Open University Press: Milton Keynes. 291pp, £17.50 (1991) (1)
Animal Model Systems to Evaluate the Antitumor Activity of Interferons (1988) (1)
Interferons: from molecular biology to man. Part 2. Interferons and cell function. (1986) (1)
Microbes, bugs and wonder drugs : potions to penicillin, aspirin to addiction (1995) (1)
Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors. (2010) (1)
Microbes, Bugs and Wonder Drugs (1995) (1)
Abstract 49: Targeting the TNF network in human ovarian cancer - A systems biology approach (2012) (1)
THE 2-5A SYSTEM AND INTERFERON ACTION (1982) (1)
Investigating the impact of London's Ultra Low Emission Zone on children's health: Children's Health in London and Luton (CHILL): Protocol for a prospective parallel cohort study (2021) (1)
The biology & clinical applications of interleukin-2 (1992) (1)
Book Review Interferon: The Science and Selling of a Miracle Drug (Routledge Studies in the History of Science, Technology and Medicine. 21.) By Toine Pieters. 264 pp., illustrated. New York, Routledge, 2005. $140. 0-415-34246-5 (2005) (1)
Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma (2020) (1)
Making small talk (2005) (1)
Abstract 4162: Interleukin–6 stimulates defective angiogenesis (2015) (1)
CXCR 2 Inhibition Profoun dly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma Graphical Abstract Highlights (2016) (1)
Enjoy Your Cells (2001) (1)
Animal Models for Studying Antitumour and Antimetastatic Activities of Interferons (1987) (1)
Interferons Combined with Other Anti-Cancer Agents — Studies in Experimental Systems (1987) (1)
Mechanisms of antitumor action of interferons on human tumour xenografts and in mouse metastases models (1987) (1)
MON-460 Pasireotide Treatment Inhibits Cytokine Release from Pituitary Adenoma-Associated Fibroblasts: Is This Mechanism Playing a Key Role in Its Effect? (2019) (1)
Immunological therapeutics in ovarian cancer (2003) (1)
Tumour Necrosis Factor: A Role in Ovarian Cancer? (1993) (1)
UK Co-ordinating Committee on Cancer Research UKCCCR Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition) UKCCCR (2002) (1)
Cytokines in Hemopoiesis, Oncology, and Immunology III (1996) (1)
MIFed about cancer? (2005) (1)
Mets and NETs: The Awakening Force. (2018) (1)
Abstract 5331: Interleukin-6 as a therapeutic target in advanced ovarian cancer (2010) (1)
Abstract 4391: CD20 as a target for therapy in solid tumors (2012) (0)
Targeting the autocrine cytokine and chemokine network of ovarian cancer (2007) (0)
Mechanisms of Anticancer Action of Interferons on Human Tumour Xenografts in Nude Mice (1987) (0)
A phase II Trial of etanercept a recombinant human soluble tumour necrosis factor receptor (p75) fusion protein in patients with metastatic breast cancer. (2003) (0)
Studying the action of IL-12 on the tumour microenvironment (1997) (0)
Tumour-associated inflammatory cytokines are reduced following primary platinum-based chemotherapy in plasma of high-grade serous ovarian cancer patients (2013) (0)
Abstract 2642: Using 3-Dimensionalin vitromodels to unravel the complexity of the metastatic microenvironment in high-grade serous ovarian cancer (2021) (0)
Cancer associated fibroblast FAK regulates malignant cell metabolism (2020) (0)
The Effect of Interferons on Cell Growth and the Cell Cycle (1979) (0)
The role of the tumour microenvironment in pituitary adenoma angiogenesis (2020) (0)
MON-462 Cytokine Network in Pituitary Adenomas and Its Role in the Tumor Microenvironment: Focus on Macrophages (2019) (0)
The relevance of animal tumour models to the preclinical screening of cytokines. (1989) (0)
Cross-talk between IKK2 and Notch promotes pancreatic cancer progression in mice through Hes1 mediated PPAR gamma inhibitio (2011) (0)
Cytokines and infections: good, bad and effective therapies? (2002) (0)
The feasibility of mice transcenic for oncogenes as therapeutic models in cytokine research (1993) (0)
Interferon γ Enhancement of Metastatic Potential by Updated Version (2006) (0)
33: Targeting cancer-related inflammation (2014) (0)
The Egg and Sperm Race (1997) (0)
Current research and treatment for epithelial ovarian cancer. A position paper from the Helene Harris Memorial Trust (vol 39, pg 1818, 2003) (2004) (0)
The chemokine network in normal and malignant cervix: CCR4 expression by malignant human cervical epithelial cells (2006) (0)
Abstract IA15: Modeling the tumor microenvironment of high-grade serous ovarian cancer (2020) (0)
Abstract 5558: Deconstruction of a human tumor microenvironment (2017) (0)
Phase I study and pharmacokinetic study PKC412, an inhibitor of protein kinase C. (2001) (0)
BIOMARKERS FOR THE PROGNOSIS AND DIAGNOSIS OF CANCER (2018) (0)
The impact of pericytes on the stability of microvascular networks in response to nanoparticles (2023) (0)
Abstract 455: B cells actively participate to the anti-cancer immune response in high grade serous ovarian cancer metastases (2015) (0)
Effect of TNF-α on Human Ovarian Cancer Xenografts in Nude Mice (1988) (0)
Abstract A31: Mutant p53 increases integrin-ECM interactions in early HGSOC (2018) (0)
Cancer Therapy : Clinical Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer (2011) (0)
42 Targeting Cytokine Networks in Malignancy (2012) (0)
10th Biennial Helene Harris Memorial Trust meeting. (2006) (0)
CCR4 as a therapeutic target for cancer (2008) (0)
Erratum to “Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust” [European Journal of Cancer, 39 (2003) 1818–1827] (2004) (0)
Toward A Tumor-Associated Phenotype Ovarian Cancer Cells Polarize Macrophages (2006) (0)
Abstract 4551: Reconstructing the metastatic tumor microenvironment of high grade serous ovarian cancer: understanding the contribution of malignant cells (2023) (0)
Pituitary tumour-derived chemokines modulate immune cell infiltrates in the tumour microenvironment leading to aggressive phenotype (2019) (0)
Abstract 591: Host cell DNA damage and inflammation responses determine oncolytic adenovirus efficacy in ovarian cancer (2010) (0)
Semi-supervised analysis of myeloid and T cell behavior in ex vivo ovarian tumor slices reveals changes in cell motility after treatments. (2023) (0)
Upregulation of amphiregulin on CD14++CD16- (classical) monocytes in non-small cell lung cancer. (2017) (0)
Regulatory T Cells + FoxP 3 Maintains a High Frequency of Functional 1-Induced CC Chemokine Ligand 22 Human T-Lymphotropic Virus Type (2010) (0)
Abstract 4576: 3D in vitro models uncover malignant cell intrinsic and extrinsic mechanisms of CAR-T cell resistance in high grade serous ovarian cancer (2023) (0)
Final general discussion (2004) (0)
Interferon treatment of human neoplasia (advances in cancer research, vol. 46) by Hans Strander, Academic Press, 1986. $44.50/£37.00 (x + 265 pages) ISBN 0 12 0066467. (1987) (0)
Inflammatory chemokines: their role in tumor growth and progression (2004) (0)
REMISSION IN ACUTE MYELOBLASTIC LEUKÆMIA (1979) (0)
Effects of HuIFN-alpha 2 and HuIFN-alpha (Namalwa) on breast cancer cells grown in culture and as xenografts in the nude mouse. (1982) (0)
S-4 : Targeting inflammatory cytokines in cancer (2014) (0)
PG 4.01 Tumor–stroma crosstalk: targeting stroma and inflammation (2015) (0)
Abstract IA23: Targeting the inflammatory cytokine network of serous ovarian cancer (2013) (0)
Effects ofintraperitoneal recombinant interleukin-lB inintraperitoneal humanovarian cancerxenograft models: comparison withtheeffects of tumournecrosis factor (1992) (0)
Re: Possible role of ovarian epithelial inflammation in ovarian cancer. (2000) (0)
A phase II trial of etanercept, a tumour necrosis factor-alpha inhibitor in recurrent ovarian cancer (2003) (0)
Cancer. Fusion potential for vaccines. (1993) (0)
Regulation and expression of argininosuccinate synthetase in human ovarian cancer (2004) (0)
Abstract A102: First‐in‐man, first‐in‐class, pharmacokinetic and pharmacodynamic phase I clinical trial of a human monoclonal antibody CNTO888 to CC‐chemokine ligand 2 (CCL2) / monocyte chemoattractant protein (MCP‐1) in patients with advanced solid tumors (2009) (0)
Targeting Inflammatory Pathways in Epithelial Ovarian Cancer (2011) (0)
A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma. (2023) (0)
Abstract 2745: Murine high grade serous ovarian cancer (HGSOC) models replicate the human tumor microenvironment and suggest anti-tumor activities of macrophages after chemotherapy (2021) (0)
From Chemistry to the Clinic: Pathways for Drug Discovery and Development. Part 2: Lead Generation, (2006) (0)
CS07-1. Inflammatory cytokines and autocrine tumour-promoting networks (2011) (0)
Abstract 5957: Chemotherapy-induced extracellular matrix remodeling in HGSOC (2023) (0)
Better late than never. Cibu foundation symposium 167; Polyfunctional Cytokines: IL‐6 and LIF (1992). Edited by Gregory R. Bock, Joan Marsh and Kate Widdows. J. Wiley & Sons. £42.50. Pp. x+279. ISBN 0471 934399 (1993) (0)
Web of intrigue (1992) (0)
Abstract 4976: Combining measures of immune infiltration uncovers predictors of survival in high-grade serous ovarian cancer (2020) (0)
Matrix metalloproteinases and their role in ovarian cancer (1995) (0)
Abstract 1094: Differential responses and mechanisms of resistance to cediranib in high grade serous ovarian cancer mouse models (2021) (0)
Promoting Diverse Youth’s Career Development through Informal Science Learning: The Role of Inclusivity and Belonging (2022) (0)
Abstract IA10: Deconstructing and reconstructing the ovarian cancer microenvironment (2018) (0)
The Effect of Human and Murine Interferons on Human Tumour Xenografts (1988) (0)
A celebration of science (2001) (0)
Interest, Mindsets and Engagement: Longitudinal Relations in Science Orientations for Adolescents in Informal Science Programs (2023) (0)
Preparing the Next Generation for STEM: Adolescent Profiles Encompassing Math and Science Motivation and Interpersonal Skills and Their Associations With Identity and Belonging (2022) (0)
Cytokine Therapeutics in Infectious Diseases (edited Steve M Holland) (2002) (0)
Impact of Youth and Adult Informal Science Educators on Youth Learning at Exhibits (2021) (0)
Interferon and cancer edited by Karol Sikora, Plenum Press, 1983. $37.50 (USA and Canada)/$45. 00 (elsewhere) (viii + 215 pages) ISBN 0 306 413795. (1984) (0)
Abstract AP24: CRISPR/CAS9–MEDIATED TRP53, BRCA1, BRCA2 AND PTEN KNOCKOUT TO GENERATE IMPROVED MURINE MODELS OF OVARIAN HIGH GRADE SEROUS CARCINOMA (2017) (0)
Ovarian Carcinoma Xenografts Tumor Burden and Prolongs Survival of Mice Bearing Human A Synthetic Matrix Metalloproteinase Inhibitor Decreases Updated (2006) (0)
Gender Stereotypes and Peer Selection in STEM Domains Among Children and Adolescents (2022) (0)
Interleukin-6 StimulatesDefectiveAngiogenesis (2015) (0)
Abstract PR14: CRISPR/Cas9-mediatedTrp53, Brca1, Brca2, Pten,andNf1knockout to generate improved murine models of ovarian high-grade serous carcinoma (2018) (0)
Morphological characterisation of adult acute leukaemia in short-term liquid culture. (1976) (0)
Phase I a nd P harmacokinetic S tudy o f P KC412, a n Inhibitor o f P rotein K inase C (2001) (0)
Abstract B53: CRISPR/Cas9 mediated p53 and BRCA2 knockout to generate improved murine models of high grade serous ovarian cancer. (2016) (0)
Abstract LB195: Immunotherapies that repolarize macrophages and CD4 T cells enhance the effect of chemotherapy in high-grade serous ovarian cancer (2023) (0)
Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours (2019) (0)
Ovarian Carcinoma Macrophages Associated with Human Chemotactic Protein-1 Receptor CCR 2 in Defective Expression of the Monocyte (1999) (0)
Abstract 2748: Impact of ARID1A mutation on the tumor microenvironment of advanced clear cell ovarian cancer (2021) (0)
Cytokines as Mediators of Disease (2003) (0)

This paper list is powered by the following services:

Other Resources About Fran Balkwill

en.wikipedia.org

What Schools Are Affiliated With Fran Balkwill?

Fran Balkwill is affiliated with the following schools: